title: [Mechanism of action of insulin sensitizer agents in the treatment of polycystic ovarian syndrome].
abstract: Polycystic ovarian disease (PCOD) is the most important endocrine abnormality that affects women in reproductive age. It is characterized by chronic anovulation and hyperandrogenemia probably secondary to insulin resistance. Hence insulin sensitizers agents had been used in PCOD. Metformin is a biguanide used in the treatment of PCOD via decrease of hepatic gluconeogenesis and insulinemia; improvement peripheral glucose utilization, oxidative glucose metabolism, nonoxidative glucose metabolism and intracellular glucose transport. Such effects, when this drug is administered alone during 3 to 6 months, increase sex hormone binding globulin (SHBG), reduce free androgens index and hirsutism, decrease insulin resistance, and regulate menses in 60 to 70% of cases. Thiazolidinodiones are drugs that decrease insulin resistance in the liver with hepatic glucose production. Their mechanism of action is through the peroxisome proliferator-activated receptors gamma (PPAR-gamma), that help to decrease plasmatic concentrations of free fatty acids, pre and postprandial glucose, insulin, triglycerides, increased HDL cholesterol and decreased LDL, menses return to normality, with improvement of ovulation and decreased hirsutism. It seems that by modulation and attenuation of insulin resistance, hypoglucemic agents such as metfomin and thiazolidinodiones can be used effectively to treat anovulation, infertility and hyperandrogenemia.
authors.affiliation: Departamento de la Reproducción Humana, Hospital Juárez de México.
authors.forename: Carlos G
authors.initials: CG
authors.lastname: Galindo García
authors.forename: Maria de Jesús
authors.initials: Mde J
authors.lastname: Vega Arias
authors.forename: Imelda
authors.initials: I
authors.lastname: Hernández Marín
authors.forename: Aquiles R
authors.initials: AR
authors.lastname: Ayala
mesh_terms: D001645:Biguanides / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance / Q000502:physiology*; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy*; D014230:Triazoles / Q000627:therapeutic use
chemical_list: D001645:Biguanides; D007004:Hypoglycemic Agents; D014230:Triazoles